- Home
- AIRE vs MRSN Comparison
AIRE vs MRSN Comparison
Compare AIRE & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRE
- MRSN
- Stock Information
- Founded
- AIRE 2021
- MRSN 2001
- Country
- AIRE United States
- MRSN United States
- Employees
- AIRE N/A
- MRSN N/A
- Industry
- AIRE
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AIRE
- MRSN Health Care
- Exchange
- AIRE Nasdaq
- MRSN Nasdaq
- Market Cap
- AIRE 33.3M
- MRSN 37.0M
- IPO Year
- AIRE N/A
- MRSN 2017
- Fundamental
- Price
- AIRE $0.41
- MRSN $6.82
- Analyst Decision
- AIRE Hold
- MRSN Strong Buy
- Analyst Count
- AIRE 1
- MRSN 3
- Target Price
- AIRE N/A
- MRSN $33.00
- AVG Volume (30 Days)
- AIRE 9.8M
- MRSN 95.6K
- Earning Date
- AIRE 08-14-2025
- MRSN 08-13-2025
- Dividend Yield
- AIRE N/A
- MRSN N/A
- EPS Growth
- AIRE N/A
- MRSN N/A
- EPS
- AIRE N/A
- MRSN N/A
- Revenue
- AIRE $3,043,657.00
- MRSN $34,769,000.00
- Revenue This Year
- AIRE $354.12
- MRSN N/A
- Revenue Next Year
- AIRE $62.13
- MRSN N/A
- P/E Ratio
- AIRE N/A
- MRSN N/A
- Revenue Growth
- AIRE 2973.28
- MRSN 16.14
- 52 Week Low
- AIRE $0.14
- MRSN $5.21
- 52 Week High
- AIRE $4.49
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- AIRE 53.91
- MRSN 42.57
- Support Level
- AIRE $0.37
- MRSN $7.41
- Resistance Level
- AIRE $0.47
- MRSN $7.55
- Average True Range (ATR)
- AIRE 0.05
- MRSN 0.50
- MACD
- AIRE 0.00
- MRSN -0.02
- Stochastic Oscillator
- AIRE 60.51
- MRSN 2.12
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.